Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

CardioKinetix brings in $44mm through its Series E venture round; closed at $48mm

Executive Summary

CardioKinetix Inc. has raised $44mm through a two-tranche Series E venture round. New investors SV Life Sciences and New Leaf Venture Partners led (and will each contribute one board member) and were joined by current shareholders US Venture Partners, JP Morgan Partners, H&Q Healthcare Investors, and H&Q Life Sciences Investors. CardioKinetix has created the CE-Marked Parachute transcatheter implant for ventricular partitioning in myocardical infarction patients.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies